The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide.
Stanley CohanTiffany Gervasi-FollmarAneesh KamathVineetha KamathChiayi ChenKyle SmootElizabeth BarabanKeith EdwardsPublished in: Multiple sclerosis journal - experimental, translational and clinical (2021)
The washout-free transition of NTZ to TFM was an efficacious and safe strategy for patients at risk of developing PML.ClinicalTrials.gov Identifier: NCT01970410.